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1 Introduction 
Statistical analysis of G-TwYST studies A, B and C were reported separately in the following reports: 
Goedhart, P.W. & van der Voet, H. (2017). G TwYST Study B. a 90-day toxicity study in rats fed GM 
maize NK603. Statistical report. Report 31.10.17, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Main statistical report. Report 32.02.18, 
Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 3 months. Report 
33.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 6 months. Report 
34.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 12 months. Report 
35.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study A. Combined chronic toxicity and 
carcinogenicity study in rats fed GM maize NK603. Statistical report, 24 months. Report 
36.02.18, Biometris, Wageningen, The Netherlands.  
Goedhart, P.W. & van der Voet, H. (2018). G TwYST Study C. a 90-day toxicity study in rats fed GM 
maize NK603. Statistical report. Report 37.03.18, Biometris, Wageningen, The Netherlands.  
Note that for Study A there are separate reports for data acquired after 3, 6, 12 and 24 months as 
well as a main report. Study B and C were 3 months studies only. The following five groups of 
endpoints were observed across studies and months: 
1. Weights: final bodyweight, growth rate and mean of feed consumption. The growth rate 
obtained after three months was defined by an exponential curve, while the growth rates 
during the months 4- 6 and 7-12 month were obtained by linear regression. The growth rate 
during the month 13-24 in study A was not estimated because the weights had an irregular 
pattern. 
2. Haematology: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, LYMR and LYMA 
3. Clinical Biochemistry: ALP, ALT, AST, BIL, ALB, TP, Glu, CHOL, TAG, Crea, Urea, cHGB, Ca, Cl, K, 
Na and P 
4. Organs weights expressed as percentage of final bodyweight: Kidney, Spleen, Liver, AdrenGl, 
Heart, Thymus and Brain. In addition for males Testis and Epididymis, and for females Ovary 
and Uterus. These endpoints were only obtained in studies B and C, i.e. after 3 months, and 
in study A after 12 months. 
5. Urine: uVol, uVolW, uLeu, uOsmoll, uKeton and upH 
In all three studies feeds with 33% inclusion rate of the near isogenic maize and the GM NK603 
maize, without and with roundup, were used. The latter two feeds were coded as NK33- and NK33+. 
In all reports the GM feeds were compared to the non-GM control feed and a 95% confidence 
interval for the ratio was reported for all endpoints listed above. In this report these 95% confidence 
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intervals are graphically displayed side-by-side such that a quick comparison can be made. The 
confidence interval are coded by “B-03” and ”C-03” for study B and C, which emphasizes that these 
are 3 months studies, and by ”A-03”, ”A-06”, ”A-12” and ”A-24” for study A. While assessing these 
figures it should be kept in mind that 
1. The four confidence interval intervals for study A, i.e. for 3, 6, 12 and 24 months, are not 
independent since they are based on the same animals; 
2. For the study A 24 month data only data for those animals that survived for two years were 
statistically analysed; 
3. The confidence intervals employed the residual variance and the associated degrees of 
freedom of a simultaneous analysis of variance of all feeds; 
4. Intervals are based on various numbers of replication, see Table 1; 
5. The Urine endpoints uLeu and uKeton only attained a limited set of values, and an analysis of 
variance might therefore not be appropriate; 
6. For intervals that do not encompass the value 1 the corresponding estimate is coloured 
fuchsia. For such endpoints there is a significant difference at the 5% level between the GM 
feed and the control feed. 
Table 1 Number of cages per feeding group classified by study and endpoint group. The number 
of cages for Study A after 24 month is variable due to animals that died before the end 
of the study. 
Endpoint group B-03 C-03 A-03 A-06 A-12 A-24 
Weights 8 8 35 35 35 17 – 23 
Haematology 8 8 20 20 20 15 – 23 
Clinical Biochemistry 8 8 20 20 20 16 – 23 
Organs 8 8 - - 10 - 
Urine 8 8 10 10 15 15 - 20 
 
In addition the coefficient of variation 𝐶𝐶𝐶𝐶, as estimated from the residual variance 𝜎𝜎2 of the analysis 
of variance on the log-transformed data, is graphically displayed for every endpoint and every study. 
The coefficient of variation, expressed as a percentage, is calculated by means of  
 𝐶𝐶𝐶𝐶 = 100 ��exp(𝜎𝜎2) − 1�. 
In general, see Figure 23 to Figure 33, the CV is largest for data acquired after 24 months in study A, 
while for the other studies there is not a clear pattern for the endpoints considered in this report. 
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Figure 1 95% confidence intervals for Weights endpoints for males. 
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Figure 2 95% confidence intervals for Weights endpoints for females. 
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Figure 3 95% confidence intervals for Haematology endpoints for NK33- / Control for males. 
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Figure 4 95% confidence intervals for Haematology endpoints for NK33+ / Control for males. 
8 
 
 
Figure 5 95% confidence intervals for Haematology endpoints for NK33- / Control for females. 
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Figure 6 95% confidence intervals for Haematology endpoints for NK33+ / Control for females. 
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Figure 7 95% confidence intervals for Clin. Biochem. endpoints for NK33- / Control for males. 
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Figure 8 95% confidence intervals for Clin. Biochem. endpoints for NK33- / Control for males. 
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Figure 9 95% confidence intervals for Clin. Biochem. endpoints for NK33+ / Control for males. 
13 
 
 
Figure 10 95% confidence intervals for Clin. Biochem. endpoints for NK33+ / Control for males. 
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Figure 11 95% confidence intervals for Clin. Biochem. endpoints for NK33- / Control for females. 
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Figure 12 95% confidence intervals for Clin. Biochem. endpoints for NK33- / Control for females. 
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Figure 13 95% confidence intervals for Clin. Biochem. endpoints for NK33+ / Control for females. 
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Figure 14 95% confidence intervals for Clin. Biochem. endpoints for NK33+ / Control for females. 
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Figure 15 95% confidence intervals for Organ endpoints for NK33- / Control for males. 
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Figure 16 95% confidence intervals for Organ endpoints for NK33+ / Control for males. 
20 
 
 
Figure 17 95% confidence intervals for Organ endpoints for NK33- / Control for females. 
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Figure 18 95% confidence intervals for Organ endpoints for NK33+ / Control for females. 
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Figure 19 95% confidence intervals for Urine endpoints for NK33- / Control for males. 
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Figure 20 95% confidence intervals for Urine endpoints for NK33+ / Control for males. 
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Figure 21 95% confidence intervals for Urine endpoints for NK33- / Control for females. 
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Figure 22 95% confidence intervals for Urine endpoints for NK33+ / Control for females. 
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Figure 23 Coefficient of variation for Weights endpoints for males (top) and females (bottom). 
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Figure 24 Coefficient of variation for Haematology endpoints for males. 
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Figure 25 Coefficient of variation for Haematology endpoints for females. 
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Figure 26 Coefficient of variation for Clinical Biochemistry endpoints for males. 
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Figure 27 Coefficient of variation for Clinical Biochemistry endpoints for males. 
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Figure 28 Coefficient of variation for Clinical Biochemistry endpoints for females. 
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Figure 29 Coefficient of variation for Clinical Biochemistry endpoints for females. 
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Figure 30 Coefficient of variation for Organ endpoints for males. 
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Figure 31 Coefficient of variation for Organ endpoints for females. 
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Figure 32 Coefficient of variation for Urine endpoints for males. 
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Figure 33 Coefficient of variation for Urine endpoints for females. 
